Q1 2024 sales update

Published
Categorized as General

Applications now open for the 2024 Golden Ticket competition

As part of our commitment to accelerating transformative research and development, we’re excited to announce that our annual Golden Ticket

Published
Categorized as General

FY 2023 results announcement 

Published
Categorized as General

Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics

Starting now and throughout 2024, Ipsen is sponsoring five talented, elite athletes on their journeys toward the 2024 Paralympic Games.

Published
Categorized as General

Examining the European Pharma legislation: EFPIA publishes the Dolon Report

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact

Published
Categorized as General

Capital Markets Day 2023

Ipsen plans to host a capital-markets day, starting at 12.30 pm GMT on 7 December 2023, at The Brewery, London. In-person attendance is by invitation only. The event will be webcast live.

Published
Categorized as General

2023 year to date and third-quarter sales results

Ipsen has published its year to date and third-quarter sales results on 26 October 2023 at 7am CET. Press release

Winner of Ipsen’s golden ticket announced as newest resident of Biolabs Hôtel Dieu 

We are pleased to announce that Hemerion has been awarded Ipsen’s golden ticket 2023, receiving a year’s free lab space at the

Published
Categorized as General

David Loew, Philippe Lopes Fernandes inaugurate Biolabs – Hôtel Dieu

Biolabs, a new biotech incubator located in the historic Hôtel Dieu, was inaugurated on 6 July 2023. As a founding

Published
Categorized as General

Ipsen’s 2022 Integrated Annual Report now available

2022 was a year of focus, momentum and growth at Ipsen. Learn about the progress we made and download the

Published
Categorized as General